pioglitazone has been researched along with Atypical Lipomatous Tumor in 1 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tontonoz, P | 1 |
| Singer, S | 1 |
| Forman, BM | 1 |
| Sarraf, P | 1 |
| Fletcher, JA | 1 |
| Fletcher, CD | 1 |
| Brun, RP | 1 |
| Mueller, E | 1 |
| Altiok, S | 1 |
| Oppenheim, H | 1 |
| Evans, RM | 1 |
| Spiegelman, BM | 1 |
1 other study available for pioglitazone and Atypical Lipomatous Tumor
| Article | Year |
|---|---|
Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor.
Topics: Adipocytes; Antigens, Differentiation; Cell Differentiation; Fibroblasts; Gene Expression Regulation | 1997 |